Real‐world data for the renal safety of abemaciclib combined with bisphosphonate in HR+/HER2− advanced breast cancer

OBJECTIVE: Our study evaluated the renal safety of abemaciclib plus endocrine therapy (ET) with bisphosphonate as a treatment option for hormone receptor positive, human epidermal growth factor receptor 2 (HER‐2) negative (HR+/HER2−) advanced breast cancer (ABC), especially with bone metastasis. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Hao, Chunfang, Bai, Xuedong, Zhang, Jie, Meng, Wenjing, Tong, Zhongsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807446/
https://www.ncbi.nlm.nih.gov/pubmed/36351632
http://dx.doi.org/10.1111/1759-7714.14715

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807446/
https://www.ncbi.nlm.nih.gov/pubmed/36351632
http://dx.doi.org/10.1111/1759-7714.14715

Ejemplares similares